BMY - Bristol Myers reports positive Phase 3 data for schizophrenia drug
2024-04-08 11:38:08 ET
More on Bristol-Myers Squibb Company
- Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)
- Bristol Myers Squibb: The Comeback Is Unfolding
- Bristol-Myers Squibb Is Not A Buy For Me
- Bristol-Myers highlights safety of KarXT schizophrenia therapy
- Bristol Myers, 2seventy bio's Abecma approved for earlier line multiple myeloma